2024
Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers—an Asian tertiary institution experience
Lee V, Loh J, Hui F, Sundar R, Tan B, Lee M, Lin H, Ong L, Visvanadan N, Ow S, Wong A, Chan G, Lim S, Lim Y, Tan D, Ang Y, Choo J, Lee M, Ngoi N, Lee S, Paxman R, Parker A, Lee Y, Lim J. Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers—an Asian tertiary institution experience. Supportive Care In Cancer 2024, 32: 762. PMID: 39482416, DOI: 10.1007/s00520-024-08940-2.Peer-Reviewed Original ResearchConceptsHair preservationGynaecological cancerChemotherapy-induced alopeciaScalp cooling therapyHair regrowthCooling therapyTaxane-based chemotherapyCycles of chemotherapyAnthracycline based chemotherapyResultsEighty-three patientsGrade (GComfort scoresWeekly paclitaxelPaclitaxel regimenBased chemotherapyComfort levelChemotherapy cyclesTerminology criteriaAdverse eventsHistorical controlsInstitutional experienceChemotherapyChemotherapy-induced hair lossDrug infusionResultsEighty-three
2016
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer
Wong A, Sundar R, Wang T, Ng T, Zhang B, Tan S, Soh T, Pang A, Tan C, Ow S, Wang L, Mogro J, Ho J, Jeyasekharan A, Huang Y, Thng C, Chan C, Hartman M, Iau P, Buhari S, Goh B, Lee S. Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Oncotarget 2016, 7: 64089-64099. PMID: 27577069, PMCID: PMC5325427, DOI: 10.18632/oncotarget.11596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnthracyclinesAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsContrast MediaCyclophosphamideDisease-Free SurvivalDoxorubicinDrug Administration ScheduleFemaleHumansImmunohistochemistryIndolesMagnetic Resonance ImagingMiddle AgedNeoadjuvant TherapyPreoperative PeriodPyrrolesSunitinibTreatment OutcomeConceptsPathological complete responseVascular normalization indexChemotherapy dose delaysLow-doseDose delaysDCE-MRIPhase IbDecreased lymphatic vessel densityIntra-tumoral drug deliveryPathologic complete response rateRecommended phase II dosePhase II doseDose of sunitinibTreatment of breast cancerDCE-MRI parametersPre-operative treatmentAnthracycline-based chemotherapyOpen-label studyRandomized to chemotherapyTumor vessel normalizationLymphatic vessel densityEnhance chemotherapy efficacyBreast cancer patientsFunctional imaging biomarkersPharmacodynamic evidence